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Two-component systems (TCS) regulate diverse processes such as virulence, stress 
responses, metabolism and antibiotic resistance in bacteria but are absent in humans, making 
them promising targets for novel antibacterials. By incorporating recently described TCS 
histidine kinase autophosphorylation inhibitors (HKAIs) into ε-poly-L-lysine capped 
nanoparticles (NPs) we could overcome the Gram negative (Gr-) permeability barrier for the 
HKAIs. The observed bactericidal activity against Gr- bacteria was shown to be due to the 
enhanced delivery and internalization of the HKAIs and not an inhibitory or synergistic effect 
of the NPs. The NPs had no adverse effects on mammalian cell viability or the immune 
function of macrophages in vitro and showed no signs of toxicity to zebrafish larvae in vivo. 
These results show that HKAIs are promising antibacterials for both Gr- and Gr+ pathogens 
and that NPs are a safe drug delivery technology that can enhance the selectivity and efficacy 
of HKAIs against bacteria.   
 
KEYWORDS 
Multi-drug resistance, Gram negative, nanotechnology, drug delivery, two-component 
systems 
GRAPHICAL ABSTRACT: FIGURE 2 
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BACKGROUND  
Infections caused by Gram negative (Gr-) multidrug-resistant (MDR) bacteria have 
become a growing challenge worldwide (1). The most important resistance problems are 
encountered in Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter spp. which 
have developed resistance to last-line antibiotics such as expanded-spectrum cephalosporins 
and/ or carbapenems (2). Besides, urinary tract infections (UTIs) caused by Gr- 
uropathogenic Escherichia coli (UPEC) are among the most common bacterial infections in 
humans and recently multi-drug resistant E. coli have been reported (3), (4), (5). For this, 
novel strategies to target infections caused by Gr- bacteria are urgently needed.  
Bacterial two-component systems (TCS) are signal transduction systems found in nearly all 
bacteria and have been proposed as promising antibacterial drug targets for both Gram 
positive (Gr+) and Gr- infections (6), (7), (8). A prototypical TCS consist of membrane 
bound histidine kinase (HK) and its cognate response regulator (RR) (9). Upon 
environmental stimuli the catalytic and ATP-binding (CA) domain of the HK 
autophosphorylates a conserved histidine found within the dimerization and histidine 
phosphotransfer (DHp) domain, which subsequently serves as the phosphodonor for a 
cognate RR (9). The changes in the phosphorylation levels of the RR are usually related to 
changes of the expression of target genes involved in the regulation of variety of processes 
including growth, virulence, antibacterial resistance and adaptation to environmental changes 
(6), (10), (11). Following structure-based and fragment-based drug discovery approaches 
(12), we have identified a set of bacterial histidine kinase autophosphorylation inhibitors 
(HKAIs) (Figure 1). These HKAIs inhibit the autophosphorylation of HKs from both Gr+ 
and Gr- bacteria, including YycG, belonging to the essential TCS YycFG found in many Gr+ 
pathogens and E. coli PhoR, belonging  to the PhoRB TCS, which regulates phosphate 
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homeostasis, adaptive stress responses and bacterial virulence (13), (14), (15), (16), (17). The 
HKAIs are bactericidal against a panel of Gr+, including methicillin-resistant Staphylococcus 
aureus (MRSA),  with minimal bactericidal concentrations (MBC) of 8-16 µg/ml (12). 
However, killing of Gr-, e.g. E. coli, was substantially less effective, presumably due to the 
composition of the lipopolysaccharide (LPS)-containing outer membrane (OM), which is 
known to hinder membrane permeability of  hydrophobic antibiotics (18), (19). The low 
permeability OM barrier of Enterobacteriaceae is a major obstacle to the discovery and 
development of effective antibiotics against enteric Gr- pathogens. One strategy to overcome 
this problem is the use of  cationic or amphiphilic molecules to facilitate permeability of the 
OM and sensitize Gr- bacteria to hydrophobic antibiotics (20), (21).  Nanomedicines have 
also been successfully used to deliver therapeutic hydrophobic and hydrophilic drugs as well 
as proteins and peptides molecules and can be equipped with targeting molecules to deliver 
their cargo to specific organs or cells (22), (23), (24).  
As delivery systems, mesoporous silica nanoparticles (MSNs) have attracted much attention 
due to their stability, biocompatibility, large load capacity and the possibility of easy 
functionalizing their surface to obtain targeting and drug release systems (25). The 
development of capped systems able to retain the payload yet releasing it upon the presence 
of a predefined stimulus has been proved to be an excellent approach to develop advanced 
nanodevices for controlled delivery applications. Although mesoporous silica supports have 
been used for the simple diffusion-controlled release of certain antibiotics (26), (27), (28), 
studies using capped materials to release MSN cargo on contact with bacteria have only 
recently been described (29). MSNs loaded with vancomycin, functionalized with n-[(3-
trimethoxysilyl)propyl]ethylendiamine (f) and capped with a cationic polymer of ε-poly-L-
lysine (ePLL) showed an extended spectrum of activity against Gr- bacteria  including E. coli 
(DH5α, 100, 405), Salmonella typhimurium and Erwinia carotovora (29). Most Gr- 
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pathogens are intrinsically resistant to vancomycin due to its relatively high molecular weight 
and size and inability to pass through porins in the OM (30), but ePLL promoted ionic 
bonding of the nanoparticles loaded with vancomycin (N.Van) with the negatively charged 
OM and facilitated membrane permeability of vancomycin (31). Moreover when ePLL and 
vancomycin were used in the N.Van nano-formulation a potent synergistic effect was 
observed which did not occur when ePLL and vancomycin were used alone (29).  
To test whether the approach described above could extend the spectrum of activity of 
the HKAIs to Gr- bacteria we loaded MSNs with different inhibitors, rhodamine as a control, 
and then capped the functionalised nanoparticles (NPs) with ePLL. The minimal inhibitory 
concentrations (MICs) of the NPs alone, NPs loaded with rhodamine and capped with  ePLL 
(N.Rho), ePLL alone, and different HKAIs loaded to nanoparticles capped with ePLL were 
determined using a standard double dilution method and compared to the free HKAIs (12), 
(32), (33), (34). A further aim was to address concerns that these engineered NPs might also 
enhance cytotoxicity of the HKAIs for human and animal cells or have detrimental effects on 
the immune function of mononuclear cells that are crucial for innate defences against 
invading pathogens and initiation of adaptive responses. Lastly, we demonstrated that the 





SYNTHESIS OF NANOPARTICLES  
 
The NPs studied here were synthesized and characterized as previously described 




Escherichia coli CFT 073, E. coli DH5α and S. marcescens 21639 were obtained from 
Leibniz Institute DSMZ – German Collections of Microorganisms and Cell Cultures 
(Braunschweig, Germany) and were propagated using standard microbiological procedures.  
 
ANTIMICROBIAL SUSCEPTIBILITY TESTING 
 
Minimal inhibitory concentrations (MICs) of MCM-41, NPs loaded with rhodamine 
and capped with  ε-poly-L-lysine (N.Rho), ePLL alone, HKAIs loaded to nanoparticles 
capped with ePLL (N.HKAIs), and HKAIs alone (F.HKAIs) were determined using a 
standard double dilution method  (32), (33), (34). Antimicrobial susceptibility testing was 
performed with inoculum of 1.105 – 1.106 CFU/ml. N.HKAIs were suspended in water and 
Mueller Hinton (MH) broth (1:1) to concentration corresponding to 1.105 µg/ml (N.B2, N.B7, 
N.B11, N.B13, N.B14, N.B15) or 2.5x104 µg/ml (N.F1.8 and N.F2.3) F.HKAIs and sonicated 
to obtain a homogenous suspension. The concentrations were chosen in relation to the IC50s 
for HK autophosphorylation inhibition (micromolar range) and the MIC against Gr+ (≤ 16 
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µg/ml) (12). In the case of N.F1.8 and N.F2.3 lower concentration ranges were tested due to 
solubility issues. The suspensions were serially diluted in MH broth in 96-well plates. The 
MIC was recorded as the lowest concentration where no visible growth was observed. 
Minimal bactericidal concentrations (MBCs) were determined by plating 10 µl of the wells 
where no growth was observed on MH agar plates and incubating overnight at 37 °C or by 
inoculating 90 µl MH broth with 10 µl of the wells where no growth was observed. MBC was 
recorded as the lowest concentration where no colonies were formed or no visible growth was 




Synergy between ε-poly-L-lysine (ePLL) and F.HKAIs  was assessed by the 
checkerboard method (35) in 96-well-plates in MH broth. Fractional inhibitory 
concentrations (FICs) were calculated based on the content in the wells in the growth-no 
growth area. FIC > 0.5 indicates no synergy (35).  
 
CELL LINES AND MEDIUM 
 
Caco-2 BBE cells (CRL 2102) and Raw 264.7 cells (Mouse leukemic monocyte 
macrophage cell line) were purchased from the American Type Culture Center (Manassas, 
VA) and grown in DMEM (Invitrogen, Paisley, UK) containing Glutamax, in RPMI 1640 
(Invitrogen, Paisley, UK) supplemented with 2mM Glutamine, in DMEM, respectively. 
Cells were grown in medium supplemented with 10% fetal bovine serum (FBS; PAA 
Laboratories, Colbe, Germany),100 U/ml penicillin and 100 μg/ml streptomycin (Sigma, St. 
Louis, MO) in an atmosphere of 5% CO2-95% O2 at 37°C and were passaged weekly. 
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NEUTRAL-RED UPTAKE ASSAY OF CELL VIABILITY 
 
Neutral-red (NR) uptake assay of cell viability with Caco-2 cells was performed as 
previously described (36). Briefly, after overnight incubation with the NPs (MCM-41, N.Rho 
and N.HKAIs), the F.HKAIs, or ePLL, 10 µl of NR solution (33 µg/ml) was added to the 
wells. After 3 h of incubation at 37°C, the medium was removed and cells were washed 
rapidly with 1x PBS. NR was extracted from the cells with 150 μl 1% acetic acid-50% 
ethanol, shaken for 10 min at RT. The NR content was measured on a SpectraMax M5 
microplate reader (Molecular Devices) at 540 nm. The readings were expressed as NR uptake 
relative to the uptake of the cells exposed to the negative control (medium or DMSO). 
 
ACTIVATION OF MACROPHAGES AND TREATMENT WITH NPS AND F.HKAIS  
 
Raw cells were seeded in 96-well-plates (1.105cells/well) and allowed to attach to the 
bottom of the wells at 37°C and 5% CO2 for 1 h. Cells were treated with NPs (MCM-41, 
N.Rho, N.HKAIs) or F.HKAIs, in the presence or absence of 1 μg/ml LPS. Controls 
containing solvent (water or DMSO) were run in parallel. A nitric oxide (NO) assay and a 
viability assay (XTT assay) were run consecutively for every treatment group (see 
Supplementary Information). The macrophages cultures were incubated at 37°C and 5% 
CO2 for 24 h before performing the appropriate assays. 
 
 
TUMOUR NECROSIS FACTOR ALPHA ELISA 
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Tumour-necrosis factor alpha (TNFα) protein levels were measured by quantitative 
enzyme linked immunosorbet assays (ELISA) using the Mouse TNF alpha ELISA Ready-
SET-Go!® reagent set (Affymetrix, eBioscience, Netherlands). Briefly, after overnight 
incubation of Raw cells with NPs or F.HKAIs, before or after stimulation with 1 µg/ml LPS, 
plates were centrifuged at 2000 rpm, at RT for 7 min. 75-μl volumes of the supernatants were 





Zebrafish (Danio rerio) were bred at the animal facility of Wageningen University 
and Research Centrum as previously described (37), (38), (39),  (37). The breeding tank was 
cleaned twice a day until hatching by removing debris and unfertilized eggs. Embryos were 
collected as eggs on different days and maintained in sterile oxygenated water at 28˚C. For 
experiments zebrafish embryos between 1 and 4 days post-hatching were used. After 4 days 
post-hatching, embryos were sacrificed by an overdose of the anesthetic 3-aminobenzoic acid 
(Tricaine, Sigma-Aldrich, USA) buffered with 1.5% NaHCO3. All zebrafish were raised, 
maintained, and handled in compliance with the local animal welfare regulations, and 
according to standard protocols (zfin.org) under the guidelines of Wageningen University and 
Research Centre Institutional Animal Care and Use Committee. 
  
INCUBATION OF ZEBRAFISH LARVAE WITH N.RHO 
 
Zebrafish were cultured to 96-well plates (1 embryo/ well) in a total volume of 100 µl 
oxygenated water at 28˚ C. Then 1, 2, 5, 10 µl of the NP stock solution (1 mg/ml) were added 
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to the wells. Each treatment group contained 5 larvae 3 days post-hatching and 5 replicates 
were tested per group. To visualize the NPs two embryos per group were anesthetized with 
200 μg/mL 3-aminobenzoic acid. Images were taken after 1.5, 6 and 24 hours post incubation 
using Leica M205 FA Fluorescence Stereo Microscope (Leica Microsystems). 
CONFOCAL MICROSCOPY   
The DH5α cells used for the confocal experiments were diluted 1/25 in Mueller-
Hinton broth from an overnight culture and were grown with 1mg/ml or 5mg/ml of ePLL-
capped NPs loaded with rhodamine (N.Rho) or empty nanoparticles supplemented with the 
same concentration of rhodamine (MCM41+Rho). After 4 hours the cells were imaged at 63 
× HCXPL APO CS2 objetive (1.40 aperture) on a Confocal Leica TCS SP8 with a 561nm 
laser (567-700nm). The fluorescence cuantification was done with 5.2 zoom (69,44 μm x 
69,44 μm),  chosing only the cytoplasmatic portion of the cell, in ImageJ version Fiji program 




SYNTHESIS AND CHARACTERIZATION OF MESOPOROUS SILICA-BASED NANOPARTICLES 
CAPPED WITH Ε-POLY-L-LYSINE AND LOADED WITH HKAIS  
 
Mesoporous silica MCM-41 nanoparticles were loaded with HKAIs or rhodamine dye 
as a control and capped with ε-poly-L-lysine (N.HKAIs or N.Rho) as previously described 
(29). Figure 2 shows a schematic representation of the expected mechanism of action of 
N.Rho and N.HKAIs solids in the presence of Gr- bacteria. Standard procedures were used to 
characterize the prepared NP solids (see Supporting Information). Transmission electron 
microscopy (TEM) confirmed the mesoporous morphology of the MCM-41 NPs (diameter 
ca. 100 nm) and in the final capped NPs (see Figure 3). Powder X-ray diffraction (PXRD), 
carried out on the starting MCM-41 NPs, showed the (100) low-angle reflection peak that is 
characteristic of these mesoporous materials. Preservation of the (100) reflection in the 
following solids (e.g. N.Rho) clearly confirmed that the loading and chemical modification 
processes did not damage the 3D mesoporous structure (see Supporting Information). 
Moreover, the N2 adsorption-desorption isotherms (see Supporting Information) were typical 
of a mesoporous material (MCM-41) and gated and filled mesoporous systems (N.Rho and 
N.HKAIs). Moreover, from thermogravimetric and elemental analyses the organic content of 
N.HKAIs and N.Rho was determined and is shown in Table 1. The content of the N.HKAIs 
was between 5 and 138 mg HKAIs/g solid (0.02 to 0.45 mM HKAI/ g solid), and the ePLL 
and silica content for the N.HKAIs or N.Rho was between 91 and 220 mg ePLL/ g solid 
(0.022 – 0.054 mmol ePLL/g solid) and between 51 and 59% silica, respectively.   
NANOPARTICLES LOADED WITH HKAIS ARE ANTIBACTERIAL 
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The antibacterial activities of N.HKAIs, F.HKAIs, ePLL, MCM-41 and N.Rho were 
evaluated by determining the optical density at 600 nm (OD600) of bacterial suspensions of E. 
coli CFT 073, E. coli DH5α, or S. marcescens 21639 incubated overnight (16 to 24 h) in 96-
well plates. The F.HKAIs did not inhibit bacterial growth at concentrations even as high as 
500 µg/ml (MIC > 500 µg/ml) with the exception of F.B14 and F.F1.8. F.B14 and F.F1.8, 
which had MICs of 500 and 250 µg/ml against E. coli CFT 073 and S. marcescens 21639 
respectively (Table 2, (12)). The antibacterial activity of the N.HKAIs against E. coli CFT 
073, E. coli DH5α, and  S. marcescens 21639 was in all cases more than 10 times lower than 
the MICs of the F.HKAIs with MICs corresponding to 3 to 100 µg/ml HK inhibitors (Table 
2). MICs corresponding to 3 to 100 µg/ml HK inhibitors are comparable to the MICs of the 
F.HKAIs against Gr+ (12) supporting a common mechanism of action, i.e. HK inhibition.  
 
ANTIBACTERIAL ACTIVITY OF N.HKAIS IS DUE TO THE HK INHIBITORS 
 
To exclude the possibility that the observed antibacterial effect of the  
nanoformulations was due to the MCM-41 particles themselves or of the ePLL we tested the 
MIC  of MCM-41 and N.Rho against E. coli CFT073 and S. marcescens (Table 3). MCM-41 
and N.Rho did not inhibit bacterial growth, even at concentrations as high as 11 mg/ml (MIC 
> 11 mg/ml) and 10 mg/ml (MIC > 10 mg/ml), respectively. 10 mg/ml N.Rho corresponds to 
1020 µg/ml ePLL (MICePLL nanoformulation > 1020 µg/ml, Table 3). The highest tested 
concentrations of MCM-41 and ePLL as part of N.Rho were higher than the MCM and ePLL 
content of the highest tested concentrations of the N.HKAIs. We also excluded the possibility 
that the observed antibacterial effect of the N.HKAIs was due to a synergistic effect of the 
HKAIs and ePLL using the checkerboard method with E. coli CFT 073 as the indicator 
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strain.  Using the same method, we also found no synergistic effect between ePLL and the 
free HK inhibitors (FICs > 0.5).   
EPITHELIAL CYTOTOXICITY OF NANOFORMULATIONS AND FREE HKAIs  
 
To be used as effective drugs, antibacterials should have high selectivity for the 
pathogen at the therapeutic concentrations reached in the body and not show toxicity to host 
cells. Although silica is generally considered to be non-cytotoxic, the ePLL-capped 
formulations of the silica-based NPs described here may affect their biocompatibility because 
of altered physicochemical properties or enhancement of HKAI toxicity to host cells. 
Therefore, to assess this we investigated the cytotoxicity of the studied NPs with and without 
incorporation of HKAIs.   
Viability of human colon carcinoma cells (Caco-2) incubated with MCM-41, N.Rho, 
N.HKAIs, F.HKAIs, or ePLL was measured using the neutral-red (NR) uptake assay (36). 
The N.HKAIs were less cytotoxic than the F.HKAIs (Table 4, Figure S3), with IC50 values   
corresponding to ≥ 100 µg/ml of the HKAIs, whereas, the IC50 values of the F.HKAIs ranged 
from 3 to 134 µg/ml. Thus the selectivity index (SI), i.e. mammalian cell cytotoxicity 
(IC50)/antibacterial effect (MIC), was improved for the N.HKAIs compared to the F.HKAIs 
(Table 4). Furthermore, MCM-41 and ePLL were not cytotoxic to Caco-2 cells at 
concentrations as high as 2742 µg/ml and 673 µg/ml, respectively, corresponding to the 
highest content of MCM-41 and ePLL present in the N.HKAIs. N.Rho was also not cytotoxic 
at 1000 µg/ml, corresponding to 102 µg/ml ePLL as part of the nanoformulation.  
 
EVALUATION OF NPS TOXICITY USING ZEBRAFISH LARVAE  
 
15  
The toxicity of the NPs capped with ePLL were also tested in vivo, using zebrafish 
larvae (40), (41), (42).  Dispersion of N.Rho in the water containing the zebrafish embryos at 
concentrations of 10, 20 and 50 µg/ml did not result in any signs of toxicity or lethality to the 
larvae for up to 24 h hours (Figure 7). Nevertheless incubation with N.Rho led to a time and 
concentration dependent increase of rhodamine fluorescence in the intestine and in the yolk 
sac (Figure 7). This can be attributed to uptake of N.Rho via the gills or the skin (43), 
distribution in the blood and accumulation in the yolk sac and intestine. The gills are 
considered to be the main site of antigen uptake in fish, although entry through the skin has 
also been shown to play a significant role (43). If N.Rho was indeed taken up via the gills, it  
might have circulated through the vasculature to the yolk sac and the intestine. A similar 
distribution in the body was observed with liposomes delivered by immersion (44). Possible 
release of the rhodamine cargo due the encounter of the N.Rho with the yolk content or with 
Gr- negative bacteria normally present in the intestine may also be a factor influencing the 
observed results.  
 
NPs AND NPs CAPPED WITH ePLL DO NOT AFFECT IMMUNE CELL FUNCTION 
Immunotoxicity and altered immune responses are unwanted side effects precluding 
the clinical use of many drugs. To investigate potential for the NPs alone or N.HKAI 
formulation to elicit or attenuate inflammatory responses, we incubated them with 
macrophages for 24h at 37ºC with 5% CO2  and measured NO production and secretion of 
pro-inflammatory cytokines such as tumour-necrosis factor alpha (TNFα). 
 
TNFα is involved in the process of inflammation and in cellular processes mediating 
protection to bacterial infections (45). Antibacterials ideally should not alter the level of 
TNFα production by activated and resting macrophages. Indeed, neither the NPs (MCM-41, 
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N.Rho or N.B13) nor the HKAI F.B13 caused changes in TNFα secretion by Raw cells 
before or after stimulation with 1 µg/ml LPS (Figure 6).  
The inducible high-output isoform of nitric oxide synthase (NOS2 or iNOS) lies at the 
interface between the innate and adaptive immune systems (46). Human NOS2 is most 
readily observed in monocytes or macrophages from patients with infectious or inflammatory 
diseases. Sustained production of NO endows macrophages with cytostatic or cytotoxic 
activity against viruses, bacteria, fungi, protozoa, helminths, and tumour cells. Other 
macrophage products such as acid, glutathione, cysteine, hydrogen peroxide, or superoxide 
enhance the antibacterial and cytotoxic actions of NO. To investigate whether the NPs and 
the HKAI F.B13 interfered with NO production by immune cells we incubated cultured 
macrophages with MCM-41, N.Rho, N.B13 and F.B13 with and without LPS (1µg/ml) 
stimulation for 16 to 24 h and then measured NO production (Figure 4 and S4). 
Simultaneously, the effect of MCM-41, N.Rho, N.B13 and F.B13 on macrophage viability 
and TNFα protein levels were evaluated using the XTT assay and TNFα ELISA respectively 
(Figure 5, 6, and S4).  
1 mg/ml MCM-41 or N.Rho did not cause significant changes in NO production by 
macrophages or in macrophage viability compared to the solvent control before or after 
stimulation with 1 µg/ml LPS. These results indicate that MCM-41 and N.Rho do not 
stimulate NO production by themselves and do not inhibit NO production induced by LPS. 
The production of NO before and after stimulation with 1 µg/ml LPS after incubation with 
N.B13 and F.B13 at concentrations corresponding to 100 µg/ml B13 was comparable to the 
solvent control. However, free HKAI F.B13 reduced viability of macrophages stimulated 
with LPS by more than 50% at a concentration of 100 µg/ml and LPS stimulated macrophage 
viability by more than 50% at a concentration of 20 µg/ml F.B13.This finding suggests that 
F.B13 might induce an increase in NO production by macrophages but this is masked by its 
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cytotoxic effect. The macrophage viability was decreased by N.B13 at concentrations 
corresponding to 100 µg/ml B13, implying that N.B13 also stimulates some NO production 
by macrophages. Nevertheless, these effects are observed at concentrations higher than the 
MIC of F.B13 for Gr+ bacteria and of N.B13 for Gr- bacteria (12) and Table 2, respectively). 
As the nanomaterials, MCM-41 and the control N.Rho did not cause significant changes in 
NO production or in macrophages viability, the N.B13 effect on NO production and 
macrophage viability can be attributed to release of the cargo, i.e. the HKAI F.B13. This is in 
agreement with the cell viability study of free HKAI F.B13 and Caco-2 cells (Table 4 and 
Figure S3) and indicates that the NPs and NPs capped with ePLL do not affect the function of 
innate immune cells. 
 
ePLL-CAPPED NPs ENHANCE THE INTERNALIZATION OF THE CARGO 
To study how the ePLL-capped NPs broaden the spectrum of the HKAIs in 
particular, and of vancomycin (29) we performed confocal microscopy experiments. 
Incubation of E. coli DH5α with ePLL-capped NPs loaded with rhodamine resulted in 
concentration-dependent internalization of rhodamine (Figure 8). Incubation of E. coli 
DH5α with MCM-41 and rhodamine separately and not as part of the nanoformulation 
did not result in internalization of rhodamine in the same experimental set up (Figure 8). 








 The growing number of reports about the spread of multi-drug resistant (MDR) Gr- 
pathogens demands urgent development of novel approaches to combat the health risks 
associated with infections caused by Gr- bacteria (1). Due to low number of new classes of 
antibacterials entering the market over the past decade and growing incidence of infections 
due to MDR bacteria, effort is also being directed towards the improving pharmacological 
properties, potency and delivery of known antibiotics (21), (47), (29), (48), (22). Here we 
employed a recently described nanotechnology approach (29), to enhance permeability of 
recently identified putative histidine kinase autophosphorylation inhibitors (HKAIs) in Gr- 
bacteria and demonstrated that they are bactericidal for Gr- bacteria (12). The previously 
reported HKAIs were bactericidal for Gr+ bacteria but not Gr- bacteria despite the fact they 
inhibit the autophosphorylation of HKs from both Gr- and Gr+ in vitro (12). The Gr+ bacteria  
tested with these HKAIs all possess homologues of an essential TCS (YycFG), which may 
explain the antibacterial bactericidal effect of the inhibitors against Gr+. However, it was 
uncertain whether the lack of bactericidal activity for Gr- bacteria was due to low 
permeability of the OM or the fact that none of the individual TCS in Gr- are essential for 
viability under laboratory growth conditions.  
The putative mechanism of action of the HKAIs is binding to the CA domain of HK and thus 
inhibiting ATP-binding and autophosphorylation of multiple HKs simultaneously. Therefore, 
in order to be active the HKAIs need to cross the bacterial cell envelope and reach the 
cytoplasm to exert their action. By incorporating the  HKAIs into ePLL-capped NPs we could 
show that they were bactericidal to Gr- bacteria at MBC comparable to that shown for the 
free HKAIs against Gr+ pathogens (Table 2, (12)).  As previously reported the HKAIs alone 
or the NPs themselves did not show antibacterial effect against Gr- (E. coli CFT073 or S. 
marcescens 21639, Table 3) (12), (29). Further antibacterial susceptibility testing in vitro and 
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synergy testing of the components of the NPs revealed that the antibacterial effect of the 
N.HKAIs was solely dependent on the release of the NP cargo (i.e, the HKAIs) and not on 
the synergistic effect between the HKAIs and ePLL, or due to the presence of MCM-41 and/ 
or ePLL in the nanoformulations. These results indicate that HK autophosphorylation is a 
relevant target for antibacterials against Gr- provided the HKAIs overcome the Gr- 
permeability barrier conferred by the LPS-containing OM. Furthermore, it indicates that 
simultaneous inhibition of multiple non-essential targets in Gr- bacteria leads  to bactericidal 
effect.    
 Furthermore, an improved selectivity index (IC50/ MIC) of the N.HKAIs compared to 
the F.HKAIs was observed (Table 4).This is an expected result because mesoporous NPs 
capped with cationic ePLL are designed to interact with the negatively charged OM of Gr- 
bacteria (29). Their proposed mechanism of action is attributed to ionic interaction of the 
positively charged ePLL capped NPs with the bacterial OM, followed by displacement and 
binding of ePLL to the Gr- cell membrane, thereby allowing the HKAIs to be released (29) 
(Figure 2). Incubation of E. coli DH5α  with the ePLL-capped NPs loaded with rhodamine, 
and a mixture of MCM-41 and rhodamine, showed that the nanoformulation enhances the 
internalization of the loaded content by E. coli DH5α in a concentration-dependent manner 
(Figure 8). Additionally, the lack of synergistic effect between MCM-41 and the capping 
ePLL on cytotoxicity and immunotoxicty of the NPs, and the lack of toxicity to zebrafish 
embryos suggest that ePLL capped mesoporous NPs are safe to be used for antibacterial drug 
delivery.  
 The broadening of the antibacterial spectrum of the small-molecule HKAIs by ePLL-
capped NPs suggests this approach has potential to be used to enhance the antibacterial 
spectrum of variety of antibiotics.   
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A major challenge while translation will be to produce silica NPs with consistent 
physico-chemical characteristics at higher concentrations. One way to address this challenge 
is to optimize the large-scale synthesis of the NPs, or synthesize more batches of NPs as done 
so far (23, 24, 29, 49). In previous work and here we have shown that there is a good batch-
to-batch reproducibility in the physicho-chemical characteristics and biological activities of 
the synthesized NPs.  
A further challenge while translation will also be to determine the route of 
administration. Most medicines can be administered by variety of routes. The choice of 
appropriate route of administration is determined based on the therapeutic objectives and on 
the properties of the drug. In the case of the ePLL-capped NPs loaded with HKAIs reported 
here the therapeutic objective would be to limit or eradicate bacterial infections caused by Gr- 
pathogens. Most common Gr- infections include recurrent urinary tract infections (UTIs), 
wound infections caused by A. baumanii and P. aeruginosa, respiratory infections by P. 
aeruginosa and other Gr- negatives, e.g. in lung disease in cystic fibrosis or nosocomial 
pneumonia, sexually transmitted infections by Neisseria gonorrhoea, bloodstream 
nosocomial infections by K. pneumoniae and P. aeruginosa, and others. To limit potential 
adverse effects, such as toxicity, interference with the host microbiota and inducing and 
spread of resistance, ideally the antibacterial NPs should be delivered locally to the site of 
infection (targeted drug delivery). In the case of UTIs, the bladder anatomy allows relatively 
easy and direct delivery of medicines through a catheter, allowing the drug to reach the target 
site with minimal side effects while avoiding first-pass metabolism. Other routes of 
administration applicable to medications for UTIs are reviewed in (50). For wound infections, 
direct delivery to the wound is the preferred option, reviewed in (51).  
Infections of the respiratory tract are some of the most common causes of human 
illness and the leading cause of death from infectious diseases worldwide (52). Systemic 
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delivery of antibacterials to treat lung infections face a number of obstacles. For example, it 
is well understood that effective antimicrobial therapy requires adequate drug concentrations 
at the target site of infection (53). To reach the deep airways in sufficient concentrations, 
high, often toxic doses of drugs would need to be given systemically. The inhalation of 
antibacterial agents on the other hand allows higher concentrations to be deposited directly in 
the lungs so that pathogens are exposed to supralethal concentrations while minimizing 
potential systemic toxicity by limiting absorption and avoiding unfavorable PK/PD 
consequences (54),  (55). Furthermore, pulmonary drug delivery allows targeting the drug 
delivery directly to lung both for local and systemic treatment (56) making it a suitable route 




By combining two recently emerged strategies, loading of nanoparticles with 
antibacterials on the one hand, and targeting TCS signalling on the other hand, it was possible 
to achieve antibacterial bactericidal effect against Gr- bacteria in vitro with inhibitors of 
bacterial HK autophosphorylation. This shows that HKAIs are bactericidal to both Gr- and 
Gr+ presumably due to inhibition of multiple targets simultaneously. The NPs loaded with 
HKAIs did not show adverse effects on mammalian cell viability, or immunotoxicty in vitro. 
In fact, the N.HKAIs showed better SI compared to the F.HKAIs. Furthermore, the NPs did 
not cause adverse effects on zebrafish embryos. All together, these open promising 
possibilities for the treatment of Gr- infections and development of novel antibacterials and/ 
or broadening the spectrum of antibacterials using NPs. 
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Figure 1. Histidine kinase autophosphorylation inhibitors (HKAIs) Selected HKAIs inhibited 
the autophosphorylation of E. coli PhoR with IC50 ranging from 0.2 to > 2 mM. The HKAIs 
showed antibacterial effect for a panel of Gram-positive bacteria (12)with MICs in the range 
of 8 to > 500 µg/ml. Only B14 and F1.8 showed antibacterial effect for Gram-negative 
bacteria with MICs ≥ 250 or ≥ 125, respectively. The IC50 (the concentration causing 50% 
reduction in autophosphorylation activity; mM) of each HKAIs for E. coli PhoR (PhoR IC50) 
is presented together with a consensus MIC (minimal inhibitory concentrations) in 
antimicrobial susceptibility testing assays with a panel of Gram-positive (Gr+) and Gram-
negative (Gr-) bacteria. 
Figure 2. Schematic representation and putative mechanism of action of the nanoparticles 
Nanometric mesoporous MCM-41 phase (ca. 100 nM; MCM-41) functionalized with n-[(3-
trimethoxysilyl)propyl]ethylendiamine triacetic acid trisodium salt (1; blue) was capped with 
ε-poly-L-lysine cationic polymer (ePLL; red rod) and loaded with histidine kinase 
autophosphorylation inhibitors (HKAIs, pink balls). Putative mechanism of action of the 
nanoparticles (NPs) is attributed to interaction of the positively charged capped NPs with the 
negatively charged Gr- bacterial cell wall and displacement of the capping ePLL which 
results in release of the loaded HKAIs inside the bacterium and subsequently to inhibition of 
two-component systems (TCS) signalling.  
Figure 3. TEM image of the inorganic MCM-41 calcined matrix (A) and some of the final 
solids (B, C, D and E, correspond to N.Rho, NB.2, NB.14 and NF1.8 final solids, 
respectively). The images clearly show the mesoporous structure of the matrix which was 
maintained after capping with ePLL and loading with HKAIs. 
 
Figure 4. Dose effects of MCM-41 (A), N.Rho (B), N.B13 (C) and F.B13 (D) on NO 
production by cultured macrophages (Raw cells). NO production is not affected by MCM-41 
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(A), N.Rho (B), N.B13 (C), F.B13 (D) or the solvents (H2O and DMSO, E) with or without 
stimulation with 1 µg/ml LPS. The results are presented relative to the NO production 
induced by stimulation with 1 µg/ml LPS. The error bars present the SEM of at least three 
independent experiments in duplicate.  
 
 Figure 5. Dose effects of MCM-41 (A), N.Rho (B), N.B13 (C) and F.B13 (D) on cell 
viability of cultured macrophages (Raw cells). Cell viability is not affected by MCM-41 (A), 
N.Rho (B) or the solvents (H2O and DMSO, E) with or without stimulation with 1 µg/ml 
LPS. Reduction in cell viability by N.B13 (C) is observed only at the highest tested 
concentration (100 µg/ml B13) with stimulation with 1 µg/ml LPS. Reduction of cell viability 
by F.B13 (D) is observed at the highest tested concentration (100 µg/ml B13) with or without 
stimulation with 1 µg/ml LPS and at 20 µg/ml B13 with stimulation with 1 µg/ml LPS. The 
results are presented relative to the viability of the solvent controls (H2O or DMSO). The 
error bars present the SEM of at least two independent experiments in duplicate. 
 
Figure 6. Dose effects of MCM-41 (A), N.Rho (B), N.B13 (C) and F.B13 (D) on TNFα levels 
of cultured macrophages (Raw cells). TNFα produced in Raw cells after incubation with 
MCM-41 (A), N.Rho (B), N.B13 (C), F.B13 (D) or by the solvents (H2O and DMSO, E) with 
or without stimulation with 1 µg/ml LPS. The results are presented relative to the TNFα 
levels after stimulation with 1 µg/ml LPS. The error bars present the SEM of at two 
independent experiments in duplicate.  
 
 Figure 7. Incubation of zebrafish embryos with N.Rho. Rhodamine fluorescence in the yolk 
sack and the intestine is increased in concentration-dependent and time-dependent manner.  
Figure 8. Confocal imaging and quantification of NPs in DH5α cells 
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(A) Confocal images with 63x objective. Internalizaiton of rhodamine is only observed in E. 
coli CFT073 incubated with ePLL-capped NPs loaded with rhodamine and not in E. coli 
CFT073 incubated with a mixture of MCM-41 and rhodamine. The internalization of 
rhodamine is concentration-dependent. (B) Quantification of rhodamine fluorescence in E. 
coli DH5α incubated for 4 h with 1 or 5 mg/ml N.Rho and empty NPs and rhodamine 
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